Clinical Trials Logo

Lung Cancer clinical trials

View clinical trials related to Lung Cancer.

Filter by:

NCT ID: NCT05859217 Not yet recruiting - Lung Cancer Clinical Trials

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

Cabatezo-1
Start date: December 2024
Phase: Phase 2
Study type: Interventional

NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzumab). In this study, investigators hypothesize that the combination of cabozantinib (a multi-kinase inhibitor) and atezolizumab will result in better therapeutic value.

NCT ID: NCT05857995 Not yet recruiting - Lung Cancer Clinical Trials

Precision Lung Cancer Survivorship Care Intervention

KYLEADSII
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The overarching goal of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program is to reduce the burden of lung cancer by offering an innovative survivorship care approach that improves lung cancer quality of life, overcomes lung cancer stigma, and helps survivors engage with care. The project involves a two-group parallel randomized clinical trial comparing the impact of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program (KLCLCSC) among lung cancer survivors (N=300) against an enhanced usual care condition (bibliotherapy+assessment) on quality of life outcomes.

NCT ID: NCT05849129 Not yet recruiting - Lung Cancer Clinical Trials

Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer

AIVAA
Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

This is a two arm RCT evaluating the effect of intravenous vitamin C versus placebo in patients with incurable non-small cell lung cancer. Participants in both arms will be receiving platinum doublet chemotherapy with or without concurrent immunotherapy as standard care. We plan to enroll 90 patients over 5 years.

NCT ID: NCT05834413 Not yet recruiting - Lung Cancer Clinical Trials

Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

This project adopts a prospective, multicenter, randomized controlled clinical study to investigate the treatment of TCM in postoperative patients with driver gene negative lung cancer, according to two phases of postoperative adjuvant therapy: (i) chemotherapy phase immunotherapy phase. In this study, 367 patients (183 in the control group and 184 in the trial group) will be observed over 4 years, and the quality of life, toxic effects and safety of this therapy will be investigated. This study will provide evidence-based evidence for the establishment and optimization of a new model of postoperative staged TCM with adjuvant chemo-immunotherapy for lung cancer.

NCT ID: NCT05807022 Not yet recruiting - Lung Cancer Clinical Trials

Evaluation of the Safety and Effectiveness of Percutaneous and Transbronchial Argon-helium Cryoablation

Start date: March 30, 2023
Phase: N/A
Study type: Interventional

The goal clinical trial is to evaluation of the safety and effectiveness of percutaneous and transbronchial argon-helium cryoablation in primary lung cancer and metastatic lung cancer. The main question it aims to answer are:Evaluation of the safety and effectiveness of percutaneous and transbronchial argon-helium cryoablation. Participants will undergo percutaneous or transbronchial argon-helium cryoablation.

NCT ID: NCT05799027 Not yet recruiting - Lung Cancer Clinical Trials

Raman Spectroscopic Analysis of Bronchoscopic Biopsy for Diagnosing Lung Cancer

Start date: March 31, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate raman spectroscopic analysis of bronchoscopic biopsy for diagnosing lung cancer in visible lesions in the airway. The main question it aims to answer are: the diagnostic efficacy raman spectroscopic analysis of bronchoscopic biopsy for diagnosing lung cancer. The bronchoscopic biopsy sample of patients with visible lesions in the airway would undergo raman spectrum analysis.

NCT ID: NCT05794607 Not yet recruiting - Lung Cancer Clinical Trials

Investigation of the Effectiveness of Tele-pulmonary Rehabilitation After Lung Resection

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

As a result of the review in the literature, no study was found in which tele-pulmonary rehabilitation was applied after physiotherapist-supervised lung resection via video conferencing. Therefore, in this study, it was planned to investigate the effectiveness of tele-pulmonary rehabilitation in patients diagnosed with lung cancer and undergoing lung resection.

NCT ID: NCT05784974 Not yet recruiting - Lung Cancer Clinical Trials

Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer

Start date: May 1, 2023
Phase: Phase 2
Study type: Interventional

Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of Cadonilimab monotherapy as neoadjuvant therapy for patients with resectable stage II-IIIA squamous cell lung cancer.

NCT ID: NCT05771207 Not yet recruiting - Lung Cancer Clinical Trials

Effects of Protein on Muscle, Gut Microbiota and Clinical Outcome in Patients With Lung Cancer-related Sarcopenia

Start date: March 2023
Phase: N/A
Study type: Interventional

Sarcopenia is common in lung cancer patients. It is one of the significant factors affecting the overall survival, radiotherapy and chemotherapy efficacy, and quality of life of patients with lung cancer. Previous studies have shown that increased protein intake can stimulate postprandial muscle synthesis, and improve muscle mass, strength, function, and overall survival. However, most previous studies have focused on the intervention of whey protein, while the protective effect of soybean protein on lung cancer-related sarcopenia (LCRS) has not yet been fully explored and reached an agreement. So, this study aims to explore the effects of soy and whey protein on muscle, gut microbiota, and clinical outcomes among patients with lung cancer-related sarcopenia, to provide a reference for further nutrition treatment.

NCT ID: NCT05770063 Not yet recruiting - Lung Cancer Clinical Trials

Effect of Compound Amino Acid Tablets on Nutritional Status of Patients With Lung Cancer

Start date: April 15, 2023
Phase: N/A
Study type: Interventional

To investigate whether compound amino acid supplementation can further promote protein synthesis and improve nutritional status for lung cancer patients.